newsfilter
← Latest News
Business Wire·

Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference

CERS
  • Cerus Corporation (NASDAQ: CERS) announced that management will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. EST.
  • A live webcast of the fireside chat will be accessible via the Investor Relations page at http://www.cerus.com/ir, with a replay available for 90 days post-event.
  • Cerus is headquartered in Concord, California, & focuses on safeguarding the global blood supply through pathogen-reduction technologies.
  • The INTERCEPT Blood System for platelets & plasma holds both CE mark & FDA approval globally, making it the only such system for these components.
  • In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for producing Pathogen Reduced Cryoprecipitated Fibrinogen Complex to treat bleeding associated with fibrinogen deficiency.
  • The INTERCEPT red blood cell system is currently under regulatory review in Europe & in late-stage clinical development in the U.S.